Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - Femasys Inc.
Summary
This financing will enable us to implement a targeted commercial team to increase our revenue potential, while delivering on our mission to bring safe, accessible, and novel options to women, said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. Silverman commented, I look forward to working with the management team at Femasys to support the mission to improve womens health with a broad portfolio of innovative products. Femasys FemaSeed\xae Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared and has received regulatory approval in Canada. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.